Evotec SE Stock

Equities

EVT

DE0005664809

Biotechnology & Medical Research

Market Closed - Xetra 11:43:13 2024-05-24 am EDT Pre-market 01:39:04 am
8.845 EUR -3.70% Intraday chart for Evotec SE 9 +1.75%
Sales 2024 * 882M 957M Sales 2025 * 1.03B 1.12B Capitalization 1.57B 1.7B
Net income 2024 * -34M -36.87M Net income 2025 * 31M 33.62M EV / Sales 2024 * 2.08 x
Net Debt 2024 * 269M 292M Net Debt 2025 * 235M 255M EV / Sales 2025 * 1.74 x
P/E ratio 2024 *
-38.1 x
P/E ratio 2025 *
33.7 x
Employees 5,061
Yield 2024 *
-
Yield 2025 *
-
Free-Float 90.64%
More Fundamentals * Assessed data
Dynamic Chart
1 day-3.70%
1 week-9.38%
Current month-9.19%
1 month-3.44%
3 months-36.78%
6 months-52.96%
Current year-58.44%
More quotes
1 week
8.81
Extreme 8.81
9.84
1 month
8.81
Extreme 8.81
10.66
Current year
8.52
Extreme 8.52
21.42
1 year
8.52
Extreme 8.52
24.44
3 years
8.52
Extreme 8.52
45.83
5 years
8.52
Extreme 8.52
45.83
10 years
2.42
Extreme 2.42
45.83
More quotes
Managers TitleAgeSince
Chief Executive Officer 61 19-06-18
Director of Finance/CFO 51 23-02-06
Chief Operating Officer 54 12-04-30
Members of the board TitleAgeSince
Chief Executive Officer 61 19-06-18
Director/Board Member 56 19-06-18
Chairman 63 14-06-16
More insiders
Date Price Change Volume
24-05-24 8.845 -3.70% 1,961,581
24-05-23 9.185 -4.37% 2,045,070
24-05-22 9.605 +0.68% 2,395,506
24-05-21 9.54 -1.50% 1,353,441
24-05-20 9.685 -0.77% 796,918

Delayed Quote Xetra, May 24, 2024 at 11:43 am EDT

More quotes
Evotec SE is a Germany-based drug discovery and development company. The company is engaged in development of new pharmaceutical products through research alliances and development partnerships with pharmaceutical and biotechnology companies, academic institutions, patient organizations and venture capital companies. The drug discovery solutions are provided in the form of fee-for-service work, integrated drug discovery alliances, development partnerships, licensing of drug candidates and consulting arrangements. Evotec SE operates in a number of areas, including neuroscience, diabetes and complications of diabetes, pain and inflammation, oncology, infectious diseases, respiratory diseases and fibrosis. Its pipeline covers a range of therapeutic areas, such as CNS Insomnia, Chronic cough, immunology & inflammation, women’s health endometriosis, nephrology, dermatological diseases, fibrotic disease and antiviral, among others.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
A-
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
8.845 EUR
Average target price
20.79 EUR
Spread / Average Target
+135.05%
Consensus